What's new

Orphan designation: Venetoclax Treatment of diffuse large B-cell lymphoma, 14/10/2016 Withdrawn

Orphan designation: Venetoclax Treatment of diffuse large B-cell lymphoma, 14/10/2016 Withdrawn

Mar 11, 2025 - 13:51
 0
Orphan designation: Venetoclax Treatment of diffuse large B-cell lymphoma, 14/10/2016 Withdrawn
Orphan designation: Venetoclax Treatment of diffuse large B-cell lymphoma, 14/10/2016 Withdrawn
Read More

Tags:

Previous Article

Orphan designation: Venetoclax Treatment of mantle cell lymphoma, 12/12/2017 Wit...

Next Article

Worldview: Trump’s Next Tariff Targets Could Be India, Brazil and Korea

Related Posts

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 11, 2025  0

Template for assessment report for the development of European Union herbal monographs and list entries

Template for assessment report for the development of E...

Feb 17, 2025  0

Orphan designation: Clofutriben Treatment of Cushing's syndrome of endogenous origin, 16/01/2025 Positive

Orphan designation: Clofutriben Treatment of Cushing&#0...

Feb 20, 2025  0